Abstract
1. Laboratory studies
Antibacterial activity of ceftizoxime, a new cephalosporin antibiotic, was studied in comparisonwith cefazolin. Ceftizoxime was more active than cefazolin against clinical isolates of E. coli, Klebsiella, P.mirabilis, P. vulgaris, Pseudomonas, Enterobacter and Serratia.
2. Clinical studies
Twenty-six patients with complicated urinary tract infections were treated with ceftizoxime intravenously at daily dose of 0.5-6.0 g for 5 days. Satisfactory clinical responses (excellent or good) were found in 18 of 24 (75%) patients.
Effective rate of each dose was as follows; 0.5g-57.1%, 1g-70%, 2g-100%. Dose responses were observed. The bacteriological test results showed the eradication of 45 in 53 strains, with eradication rate of 84.9%.
No serious side effect was noticed with the drug, though nausea and headache were observed in one case.
In laboratory findings eosinophile was increased inone case.
